449 related articles for article (PubMed ID: 25378534)
21. Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics.
Mathur A; Arora T; Liu L; Crouse-Zeineddini J; Mukku V
J Immunol Methods; 2013 Apr; 390(1-2):81-91. PubMed ID: 23384837
[TBL] [Abstract][Full Text] [Related]
22. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
Gurbaxani B; Dostalek M; Gardner I
Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
[TBL] [Abstract][Full Text] [Related]
23. Characterization of the interactions of rabbit neonatal Fc receptor (FcRn) with rabbit and human IgG isotypes.
Szikora B; Hiripi L; Bender B; Kacskovics I; Iliás A
PLoS One; 2017; 12(9):e0185662. PubMed ID: 28957416
[TBL] [Abstract][Full Text] [Related]
24. In Translation: FcRn across the Therapeutic Spectrum.
Qi T; Cao Y
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802650
[TBL] [Abstract][Full Text] [Related]
25. Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,).
West AP; Bjorkman PJ
Biochemistry; 2000 Aug; 39(32):9698-708. PubMed ID: 10933786
[TBL] [Abstract][Full Text] [Related]
26. Human IgG lacking effector functions demonstrate lower FcRn-binding and reduced transplacental transport.
Stapleton NM; Armstrong-Fisher SS; Andersen JT; van der Schoot CE; Porter C; Page KR; Falconer D; de Haas M; Williamson LM; Clark MR; Vidarsson G; Armour KL
Mol Immunol; 2018 Mar; 95():1-9. PubMed ID: 29367080
[TBL] [Abstract][Full Text] [Related]
27. Characterization of the 2:1 complex between the class I MHC-related Fc receptor and its Fc ligand in solution.
Martin WL; Bjorkman PJ
Biochemistry; 1999 Sep; 38(39):12639-47. PubMed ID: 10504233
[TBL] [Abstract][Full Text] [Related]
28. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
Wang Y; Tian Z; Thirumalai D; Zhang X
J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
[TBL] [Abstract][Full Text] [Related]
29. Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants.
Raghavan M; Bonagura VR; Morrison SL; Bjorkman PJ
Biochemistry; 1995 Nov; 34(45):14649-57. PubMed ID: 7578107
[TBL] [Abstract][Full Text] [Related]
30. Mapping the Binding Interface in a Noncovalent Size Variant of a Monoclonal Antibody Using Native Mass Spectrometry, Hydrogen-Deuterium Exchange Mass Spectrometry, and Computational Analysis.
Yan Y; Wei H; Jusuf S; Krystek SR; Chen J; Chen G; Ludwig RT; Tao L; Das TK
J Pharm Sci; 2017 Nov; 106(11):3222-3229. PubMed ID: 28634122
[TBL] [Abstract][Full Text] [Related]
31. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences.
Wang W; Lu P; Fang Y; Hamuro L; Pittman T; Carr B; Hochman J; Prueksaritanont T
Drug Metab Dispos; 2011 Sep; 39(9):1469-77. PubMed ID: 21610128
[TBL] [Abstract][Full Text] [Related]
32. Effect of individual Fc methionine oxidation on FcRn binding: Met252 oxidation impairs FcRn binding more profoundly than Met428 oxidation.
Gao X; Ji JA; Veeravalli K; Wang YJ; Zhang T; Mcgreevy W; Zheng K; Kelley RF; Laird MW; Liu J; Cromwell M
J Pharm Sci; 2015 Feb; 104(2):368-77. PubMed ID: 25175600
[TBL] [Abstract][Full Text] [Related]
33. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.
Lu Y; Vernes JM; Chiang N; Ou Q; Ding J; Adams C; Hong K; Truong BT; Ng D; Shen A; Nakamura G; Gong Q; Presta LG; Beresini M; Kelley B; Lowman H; Wong WL; Meng YG
J Immunol Methods; 2011 Feb; 365(1-2):132-41. PubMed ID: 21185301
[TBL] [Abstract][Full Text] [Related]
34. The Fab region of IgG impairs the internalization pathway of FcRn upon Fc engagement.
Brinkhaus M; Pannecoucke E; van der Kooi EJ; Bentlage AEH; Derksen NIL; Andries J; Balbino B; Sips M; Ulrichts P; Verheesen P; de Haard H; Rispens T; Savvides SN; Vidarsson G
Nat Commun; 2022 Oct; 13(1):6073. PubMed ID: 36241613
[TBL] [Abstract][Full Text] [Related]
35. Characterization and screening of IgG binding to the neonatal Fc receptor.
Neuber T; Frese K; Jaehrling J; Jäger S; Daubert D; Felderer K; Linnemann M; Höhne A; Kaden S; Kölln J; Tiller T; Brocks B; Ostendorp R; Pabst S
MAbs; 2014; 6(4):928-42. PubMed ID: 24802048
[TBL] [Abstract][Full Text] [Related]
36. Engineered human IgG antibodies with longer serum half-lives in primates.
Hinton PR; Johlfs MG; Xiong JM; Hanestad K; Ong KC; Bullock C; Keller S; Tang MT; Tso JY; Vásquez M; Tsurushita N
J Biol Chem; 2004 Feb; 279(8):6213-6. PubMed ID: 14699147
[TBL] [Abstract][Full Text] [Related]
37. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.
Souders CA; Nelson SC; Wang Y; Crowley AR; Klempner MS; Thomas W
MAbs; 2015; 7(5):912-21. PubMed ID: 26018774
[TBL] [Abstract][Full Text] [Related]
38. Characterization of IgG1 conformation and conformational dynamics by hydrogen/deuterium exchange mass spectrometry.
Houde D; Arndt J; Domeier W; Berkowitz S; Engen JR
Anal Chem; 2009 Apr; 81(7):2644-51. PubMed ID: 19265386
[TBL] [Abstract][Full Text] [Related]
39. Impact of IgG2 high molecular weight species on neonatal Fc receptor binding assays.
Zhang Y; Mathur A; Maher G; Arroll T; Bailey R
Anal Biochem; 2015 Nov; 489():25-31. PubMed ID: 26255698
[TBL] [Abstract][Full Text] [Related]
40. Development and applications of AlphaScreen-based FcRn binding assay to characterize monoclonal antibodies.
Wu Q; Lee HY; Wong PY; Jiang G; Gazzano-Santoro H
J Immunol Methods; 2015 May; 420():31-7. PubMed ID: 25837414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
